Phase 2 Multiple Sclerosis Trial, Recruiting NCT07282574 Sponsor: Hoffmann-La Roche Condition: Multiple Sclerosis
Back to Multiple Sclerosis

Phase 2 Multiple Sclerosis Trial, Recruiting

NCT07282574
Recruiting Phase 2 🇦🇺 Australian site

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • You have been diagnosed with Progressive Multiple Sclerosis (MS), confirmed using a specific set of medical guidelines called the 2017 McDonald criteria
  • Your level of physical disability, as measured by a standard MS scoring scale, falls within a moderate range (between 3.0 and 6.0 on this scale — confirm with trial site if unsure of your score)

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • You have had an MS relapse (a flare-up of symptoms) in the 6 months before joining the trial
  • Doctors are unable to access a vein in your arm or hand for injections or blood draws
  • You have a history of alcohol or drug misuse within the past 5 years, based on the doctor's assessment
  • You are unable to have an MRI scan for any reason
  • You have a medical reason that prevents you from taking certain medications that must be given alongside the trial treatment (confirm with trial site)
  • You have received a treatment called intravenous immunoglobulin (a blood-derived therapy given through a drip) or a blood-filtering treatment called plasmapheresis within the 12 weeks before joining the trial

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 30 July 2026

Contact this trial

Principal Investigator: Clinical Trials, Hoffmann-La Roche

Phone: 888-662-6728 (U.S. Only)

Australian sites

Southern Neurology, Kogarah, New South Wales
John Hunter Hospital, New Lambton Heights, New South Wales
Box Hill Hospital, Box Hill, Victoria
Austin Health, Heidelberg, Victoria

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
10 March 2026
Est. completion
30 May 2028

Where this trial is recruiting

🇦🇺 Australia 🇫🇷 France 🇩🇪 Germany 🇭🇺 Hungary 🇮🇹 Italy 🇳🇿 New Zealand 🇵🇱 Poland 🇵🇹 Portugal 🇪🇸 Spain Turkey (Türkiye) 🇬🇧 United Kingdom

4 site(s) in Australia. Confirm current status and contact details directly with the trial site.

Primary endpoints

Time From Randomization to the First Occurrence of Composite Confirmed Disability Progression (cCPD) Confirmed for at Least 12 Weeks (cCDP12)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 30 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov